If you have a family history of early cardiovascular disease, stroke, or cognitive decline, or if you want to understand your methylation and B-vitamin adequacy beyond standard nutrition screening, homocysteine reveals whether your body is efficiently processing methionine and maintaining the one-carbon cycle. Unlike some biomarkers, homocysteine is not a direct causal driver of disease, but elevated levels flag metabolic dysfunction and B-vitamin insufficiency that cluster with vascular risk and cognitive aging.

Homocysteine testing matters especially if you are vegetarian or vegan (higher risk of B12 deficiency), have a personal or family history of neural tube defects or cognitive decline, take medications like metformin or proton-pump inhibitors that interfere with B-vitamin absorption, or have conditions like hypothyroidism or renal impairment that elevate homocysteine. It also provides context if you are considering pregnancy or have had a prior thrombotic event — elevated homocysteine is one modifiable risk factor in that milieu.

This marker sits at the intersection of nutritional status, genetic methylation capacity, and vascular health, making it a useful diagnostic breadcrumb in preventive medicine rather than a standalone treatment target.

• Reveals B-vitamin and methylation adequacy. Elevated homocysteine is the clinical footprint of insufficient B12, folate, or B6 — the three cofactors that drive homocysteine remethylation and transsulfuration. Testing homocysteine offers a functional window into nutritional status that standard B-vitamin levels alone may miss.

• Flags vascular dysfunction and endothelial stress. Homocysteine is directly toxic to the endothelium and impairs vasodilation via nitric oxide inactivation. Even modest elevation (12–15 µmol/L) correlates with arterial stiffness, endothelial dysfunction, and adverse remodeling — changes visible on vascular imaging.

• Identifies thromboembolic and stroke risk context. Homocysteine activates tissue factor and promotes thrombosis independently of atherosclerosis. Elevated homocysteine increases stroke risk 2–4-fold and venous thromboembolism risk significantly; it is a legitimate risk marker in that domain even if lowering it pharmacologically does not reduce events.

• Connects to cognitive aging and dementia risk. Prospective cohort studies link elevated homocysteine (typically >15 µmol/L) to accelerated cognitive decline and higher dementia risk, likely via vascular stiffness, impaired cerebral blood flow, and oxidative stress in the brain. This makes it a relevant preventive marker for cognitive longevity.

• Detects renal dysfunction and metabolic complications. Chronically elevated homocysteine signals either primary metabolic or nutritional dysfunction or secondary renal impairment, hypothyroidism, or genetic polymorphisms (MTHFR variants). Testing clarifies whether B-vitamins, thyroid support, or renal evaluation is warranted.

• Contextualizes treatment response in high-risk cohorts. In people with prior cardiovascular or thrombotic events, persistently elevated homocysteine despite B-vitamin supplementation may indicate genetic methylation impairment (MTHFR C677T, cystathionine-β-synthase variants) or secondary causes requiring deeper investigation.

Homocysteine metabolism and the one-carbon cycle. Homocysteine is an intermediate amino acid formed when the body metabolizes methionine, an essential amino acid from dietary protein. The body then has two main fates for homocysteine: remethylation back to methionine (using B12 and folate as cofactors), or transsulfuration to cysteine (using B6 and the enzyme cystathionine-β-synthase). Efficient flux through these pathways keeps homocysteine concentration low (<9 µmol/L). When B12, folate, or B6 becomes insufficient, or when genetic variants impair enzyme function, homocysteine accumulates in the plasma.

Why elevated homocysteine damages blood vessels and increases vascular risk. Circulating homocysteine is directly toxic to the endothelium — the inner lining of blood vessels. It oxidizes and cross-links collagen and elastin in the arterial wall, reducing compliance. It inactivates nitric oxide, a key vasodilator, impairing endothelium-dependent vasodilation and promoting vasoconstriction. At the same time, homocysteine activates tissue factor on endothelial and blood cells, tipping the coagulation cascade toward thrombosis. This means elevated homocysteine drives both structural vascular damage (atherosclerosis acceleration and arterial stiffness) and functional thrombotic risk (clot formation). The two pathways explain why people with elevated homocysteine face both ischaemic stroke and venous thromboembolism.

The homocysteine-lowering trials: causation vs. association. For decades, homocysteine was assumed to be a causal cardiovascular risk factor worth treating directly. Large RCTs (NORVIT, HOPE-2, SEARCH) randomized tens of thousands of patients with elevated homocysteine or prior MI to aggressive B-vitamin supplementation to lower homocysteine versus placebo. The trials showed that B-vitamin therapy did lower homocysteine by 20–30%, but it did not reduce cardiovascular events, MI, or mortality. Mendelian randomization studies confirm the finding: genetic variants that raise homocysteine predispose to disease, but the variants that lower homocysteine do not protect. This reveals that homocysteine is a marker of underlying metabolic and genetic dysfunction rather than a causal lever. The implication: optimizing B-vitamin status matters for health, but the goal is not homocysteine reduction per se — it is adequate methylation and metabolic function.

• Identifies modifiable B-vitamin and nutritional gaps. Unlike genetic lipid risk (Lp(a)) or insulin resistance (which respond slowly to intervention), elevated homocysteine often reflects correctable deficiencies in B12, folate, or B6. Detecting and correcting these gaps optimizes methylation, supports cognitive health, and normalizes vascular endothelial function — benefits that extend beyond homocysteine itself.

• Reveals endothelial dysfunction and vascular aging. Even mild homocysteine elevation (9–15 µmol/L) correlates with arterial stiffness, impaired flow-mediated dilation, and atherosclerotic burden on ultrasound. Because endothelial dysfunction is a upstream driver of atherosclerosis, hypertension, and cognitive decline, a mildly elevated homocysteine is a red flag to investigate vascular health holistically — paired with ApoB, hs-CRP, and blood pressure trends.

• Thromboembolic and stroke risk stratification. Homocysteine is one of the few modifiable risk factors specific to thrombotic stroke and venous clot risk. In people with prior thromboembolism, atrial fibrillation, or hypercoagulable tendencies, elevated homocysteine adds mechanistic context: it is not just a lipid or inflammatory marker, but a direct thrombosis driver. Understanding this guides anticoagulation strategy and the intensity of B-vitamin repletion.

• Cognitive aging and dementia prevention relevance. Homocysteine >15 µmol/L is associated with 2–3-fold increased dementia and cognitive decline risk in prospective cohorts. The mechanism likely involves vascular stiffness reducing cerebral perfusion and accumulation of oxidative stress. Unlike many dementia risk factors, B-vitamin status is modifiable, making homocysteine a preventive marker for cognitive longevity.

• Standard Swedish clinical reference (<15 µmol/L): This is what a typical vårdcentral would report as “normal”. Values <15 µmol/L do not trigger clinical flagging in most labs, and many people in this range have no metabolic or nutritional concerns.

• Borderline or mild elevation (9–15 µmol/L): Values in this range indicate suboptimal methylation or early B-vitamin insufficiency, particularly if B12 or folate are also at the low-normal end. This tier is often where functional B-vitamin deficiency begins to manifest vascular or cognitive effects, even though it is not flagged “abnormal” by standard reference ranges.

• Loovi optimal (longevity baseline): <9 µmol/L. Aligns with the lowest cardiovascular and cognitive risk in prospective cohort studies and reflects robust methylation capacity and B-vitamin adequacy. Most people without nutritional deficiency or genetic impairment maintain levels in this range.

• Hyperhomocysteinaemia (>15 µmol/L): Indicates material B-vitamin insufficiency, genetic methylation impairment (MTHFR, CBS variants), or secondary causes (renal impairment, hypothyroidism). Requires investigation and intervention.

The step from <9 to 9–15 µmol/L represents a functional B-vitamin adequacy threshold. Even people in the 9–15 range who are asymptomatic may benefit from investigation and optimization of B-vitamin status. Values >15 µmol/L almost always warrant B12, folate, and B6 assessment, thyroid screening, and renal function evaluation.

Low or optimal (<9 µmol/L). This indicates adequate B-vitamin status, intact methylation capacity, and favorable vascular endothelial function. In the absence of other risk factors (elevated ApoB, hs-CRP, or HbA1c), this level is associated with the lowest long-term cardiovascular and cognitive risk. Most health-conscious adults maintaining adequate B12, folate, and B6 through diet or supplementation maintain levels in this range.

Borderline-elevated (9–15 µmol/L). This indicates suboptimal B-vitamin adequacy or early functional deficiency, even if formal B12 or folate levels appear “normal”. Many people in this range have normal cognitive and cardiovascular function, but they are at higher risk for future decline and vascular dysfunction compared to those <9 µmol/L. Investigation of B12, folate, and B6 status is warranted. Pair this result with other metabolic markers: if ApoB is also elevated, vascular risk compounds.

Elevated (15–30 µmol/L). This indicates material B-vitamin insufficiency, impaired methylation, or secondary causes. Possible drivers include vitamin B12 deficiency (most common), folate deficiency (especially in those consuming little fortified grain or leafy greens — relevant in Sweden where folic acid fortification is not mandatory), B6 deficiency, renal impairment with reduced homocysteine clearance, hypothyroidism, or genetic variants in methylenetetrahydrofolate reductase (MTHFR) or cystathionine-β-synthase. This level carries increased vascular and cognitive risk and warrants investigation and intervention.

Very high (>30 µmol/L). This is unusual outside of advanced renal disease and demands investigation for severe B12 deficiency, severe folate deficiency, genetic homocystinuria (CBS deficiency), advanced chronic kidney disease, or undiagnosed hypothyroidism. This level carries material thrombotic and vascular risk and requires clinical action.

Factors that influence homocysteine. Fasting state matters — homocysteine should be measured fasting or at least several hours post-meal, as transient post-prandial elevation can occur. Renal function is critical: creatinine >100 µmol/L or eGFR <60 mL/min/1.73m² elevates homocysteine significantly. Age and male sex tend to raise homocysteine slightly. Smoking and high caffeine intake elevate homocysteine modestly. Hormone replacement therapy and hormonal contraception may lower homocysteine slightly. Intense exercise within 24 hours can transiently lower homocysteine.

• Vitamin B12 deficiency. B12 is a critical cofactor in homocysteine remethylation. Deficiency from inadequate intake (vegetarian/vegan diet without fortified foods or supplements), pernicious anaemia (autoimmune B12 malabsorption), or medications interfering with absorption (metformin, proton-pump inhibitors, H2-receptor antagonists) elevates homocysteine. B12 deficiency is the most common modifiable cause of hyperhomocysteinaemia and is easily detected and corrected.

• Folate deficiency. Folate is the other critical remethylation cofactor. Insufficiency arises from low vegetable intake, alcohol use (which impairs folate absorption and metabolism), or medications like methotrexate. Sweden lacks mandatory folic acid fortification of grain products (unlike the United States), making dietary folate intake more variable and folate insufficiency more common in Sweden than in some other countries. Folate deficiency elevates homocysteine and increases neural tube defect risk in pregnancy.

• Vitamin B6 deficiency. B6 is essential for the transsulfuration pathway (conversion of homocysteine to cysteine). Deficiency is less common than B12 or folate insufficiency but can occur with inadequate meat, poultry, legume, or whole-grain intake, or with medications like isoniazid or corticosteroids. B6 insufficiency contributes to elevated homocysteine and impaired cysteine synthesis.

• Renal impairment and glomerular filtration loss. The kidneys clear homocysteine via glomerular filtration. Chronic kidney disease (eGFR <60 mL/min/1.73m²) causes secondary homocysteine elevation independent of B-vitamin status. This is a major driver of hyperhomocysteinaemia in older adults and in people with diabetes or hypertension. In advanced renal disease, homocysteine can rise 2–5-fold above normal.

• Genetic variants in methylation enzymes. Polymorphisms in MTHFR (methylenetetrahydrofolate reductase), CBS (cystathionine-β-synthase), or other one-carbon cycle enzymes can impair homocysteine metabolism. The MTHFR C677T variant is common (30–35% of populations carry at least one copy) and is associated with slightly elevated homocysteine, especially if folate status is inadequate. CBS deficiency causes homocystinuria, a rare metabolic disorder with severe vascular and neurological consequences. Most genetic variants cause modest homocysteine elevation responsive to B-vitamin supplementation.

• Hypothyroidism and thyroid dysfunction. Thyroid hormone regulates one-carbon metabolism. Hypothyroidism elevates homocysteine independent of B-vitamin status. Correcting thyroid function (TSH <2.5 mIU/L) typically normalizes homocysteine. This is why thyroid screening is warranted in people with unexplained homocysteine elevation.

• Medications interfering with B-vitamin absorption or metabolism. Metformin (reduces B12 absorption), proton-pump inhibitors and H2-receptor antagonists (reduce intrinsic factor and B12 absorption), and methotrexate (impairs folate metabolism) all elevate homocysteine. If elevated homocysteine coincides with these medications, supplementation or medication adjustment may be warranted.

B-vitamin repletion and dietary adequacy. The primary lever is ensuring adequate intake of B12, folate, and B6. Dietary sources of B12 include meat, fish, eggs, and dairy; vegans and vegetarians require fortified foods or supplements. Folate-rich foods include leafy greens (spinach, kale), legumes (lentils, chickpeas), and asparagus; whole grains and some fortified cereals provide folate but fortification levels are lower in Sweden than in North America. B6 is found in poultry, fish, potatoes, chickpeas, and bananas. For many people, especially those with risk factors (vegetarian diet, medications impairing absorption), targeted B-vitamin supplementation — B12 (1000–2000 µg sublingual or intramuscular depending on absorption), methylfolate (500–1000 µg), and B6 (10–25 mg) — normalizes homocysteine and restores methylation capacity. The dosing and route depend on the individual’s absorption capacity and genetic factors.

Renal function optimization. If homocysteine is elevated and renal function is borderline (eGFR 45–60 mL/min/1.73m²), protecting kidney function becomes a priority. Controlling blood pressure, managing blood glucose (especially if diabetic), reducing sodium intake, and avoiding nephrotoxic drugs all slow renal decline and prevent further homocysteine elevation. In advanced renal disease, homocysteine may not normalize with B-vitamins alone; dialysis-related clearance becomes the limiting factor.

Thyroid function assessment and correction. If thyroid-stimulating hormone (TSH) is >2.5 mIU/L or free T4 is low-normal, thyroid hormone replacement typically lowers elevated homocysteine. This is a quick, high-yield intervention if thyroid dysfunction is present.

Lifestyle and metabolic optimization. Regular physical activity, adequate sleep, stress management, and moderate alcohol consumption all support B-vitamin status and methylation. Chronic alcohol use impairs folate absorption and metabolism; reducing intake improves homocysteine. Cigarette smoking elevates homocysteine modestly; cessation helps. While these are general metabolic principles rather than direct homocysteine levers, they contextualize the broader health environment in which homocysteine sits.

Limiting evidence for direct pharmacotherapy. As noted earlier, the large RCTs of aggressive B-vitamin supplementation to lower homocysteine in people with prior cardiovascular disease did not reduce events, reframing supplementation as addressing nutritional deficiency rather than as primary disease treatment. Correcting B-vitamin insufficiency is worthwhile for metabolic health and vascular function. However, there is no evidence that pushing homocysteine far below 9 µmol/L via pharmacotherapy reduces cardiovascular or cognitive events beyond the benefit of maintaining adequate B-vitamin status.

The right intervention depends on the root cause: Is homocysteine elevated because of inadequate B-vitamin intake (corrected by dietary change or supplementation), renal impairment (managed by nephroprotection), thyroid dysfunction (treated with thyroid hormone), or genetic metabolic impairment (often partially responsive to high-dose B-vitamins)? This is precisely the kind of diagnostic differentiation that a Loovi longevity doctor clarifies in consultation, using the full biomarker context to tailor intervention.

Homocysteine elevation can signal many different underlying problems — nutritional deficiency, genetic impairment, renal disease, or thyroid dysfunction — and without context markers, you cannot distinguish between them. A person with homocysteine of 12 µmol/L and normal B12 and folate levels may have a MTHFR polymorphism or early renal impairment requiring different intervention than someone with frank B12 deficiency. Conversely, someone with mildly elevated homocysteine but excellent cardiovascular markers (ApoB <0.7 g/L, hs-CRP <1.0 mg/L, HbA1c <5.2%) and robust renal function may warrant only nutritional optimization, not intensive intervention.

Moreover, homocysteine must be paired with vitamin B12, folate, and B6 levels to assess nutritional adequacy, and with thyroid function (TSH, free T4) and renal function (creatinine, eGFR) to rule out secondary causes. The relationship between homocysteine and vascular risk is also mediated by concurrent lipid (ApoB, triglycerides), inflammatory (hs-CRP), and glucose control (HbA1c) markers; context is essential for risk stratification.

The Loovi Membership measures 120+ biomarkers annually, including the full metabolic and B-vitamin profile (B12, folate, B6, homocysteine, methylmalonic acid where relevant), renal function (creatinine, eGFR), thyroid status (TSH, free T4), and cardiovascular context markers (ApoB, hs-CRP, HbA1c). Paired with unrushed 1-on-1 longevity doctor consultations, physical performance tests (strength, mobility, VO2 max), and an evolving personalized health plan, Loovi hands off the diagnostic work and treatment planning to clinical experts. From 295 SEK/month, Friskvårdsbidrag-approved, with drop-in testing at 80+ Swedish clinics and results in 3 days.